Biocon Expects ‘Successful’ US Trastuzumab Launch Despite Amgen Debut

 
• By Penelope MacRae

India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.

Spacecraft
With Rocketing Profits, Biocon Is Looking Forward To A Successful Launch • Source: Shutterstock

More from Biosimilars

More from Products